---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-004971"
form_type: "8-K"
ticker: "ALLR"
cik: "0001860657"
company_name: "Allarity Therapeutics, Inc."
filed_at: "2025-02-25T23:59:59+00:00"
generated_at: "2026-05-26T04:58:43.000299+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Allarity initiates new Phase 2 protocol for stenoparib in advanced ovarian cancer

## Summary
- Patient enrollment begins at US sites with new drug product delivered for new Phase 2 protocol.
- Two patients in ongoing phase 2 remain on stenoparib for over 17 months without progression.
- Protocol incorporates FDA feedback and IRB approval; critical data expected by end of summer 2026 for pivotal trial.
- Trial will evaluate stenoparib-DRP companion diagnostic alongside drug for dual regulatory submission.
- Targets $9B+ PARP inhibitor market and addresses FDA Project Optimus dose-finding guidance.

## SEC filing metadata
- accession: 0001437749-25-004971
- form_type: 8-K
- ticker: ALLR
- cik: 0001860657
- company_name: Allarity Therapeutics, Inc.
- filed_at: 2025-02-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860657/000143774925004971/0001437749-25-004971-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860657/000143774925004971/allr20250224_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-004971
- JSON: https://secwatch.observer/filing/0001437749-25-004971.json
- Plain text: https://secwatch.observer/filing/0001437749-25-004971.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.